# Transpek Industry share price today (Transpek Industry Ltd, NSE: TRANSPEK)

> Transpek Industry share price today: ₹1,255.80 at the NSE close on 3 November 2026, down 12.0% in a year. Transpek Industry (NSE: TRANSPEK) is worth ₹701 crore, trades at a P/E of 18.0 and has closed between ₹909.25 and ₹1,438.80 over the past 52 weeks. > Transpek Industry Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TRANSPEK · Speciality Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/transpek-industry-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from fewer quarters than usual
- Price: ₹1,255.80 (−12.0% in a year)
- P/E: 18.0× (higher than 59% of the last 11 years)
- Revenue (Jun 2026): ₹151 Cr (−2.1% on a year ago)
- Profit (Jun 2026): ₹8.9 Cr (−42.7% on a year ago)
- Operating margin: 13.3% (−2.3 points on a year ago)
- ROCE: 8%, FY26
- Profit that came in as cash: 232%, last 3 years

Biggest thing to watch: the price has already been rising for 8 weeks, so timing is the risk more than the business. ## What is the Transpek Industry share price today? Transpek Industry Ltd's share price was ₹1,255.80 at the close on 3 November 2026. It has been rising for 8 weeks. That is 2.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹909 and ₹1,439, and at that close it sat 65% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 17 weeks in a row. Over the last 11 years the share price moved +241% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Transpek Industry this quarter? 2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 1.6% to 0.2% of the company by the September 2026 quarter. 3. Revenue down on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹151 crore, -2.1% on a year earlier. Why: Revenue fell because export demand was weak and the market had too much supply, which kept prices aggressive. Next results: check whether revenue growth reaches the stated floor, helped by more acid chloride sales and a pickup in demand. From the earnings call on 20 Aug 2026. ## What are Transpek Industry's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Transpek Industry reported revenue of ₹151 crore, down 2.1% from ₹154 crore a year earlier, and a profit of ₹8.93 crore, down 42.7% from ₹15.6 crore. ### Transpek Industry results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹151 crore | ₹154 crore | −2.1% |
| Profit | ₹8.93 crore | ₹15.6 crore | −42.7% |
| Earnings per share | ₹15.99 | ₹27.89 | −42.7% |
| Operating margin | 13.3% | 15.6% | −2.3 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Transpek Industry's management discussed these results on a call held on 20 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Transpek Industry share price history? Transpek Industry closed at ₹1,255.80 on 3 November 2026, down 12.0% from ₹1,427.30 a year earlier (31 October 2025) and down 48.5% over five years. Its highest weekly close since March 2016 was ₹2,440.30 on 4 November 2021. ### Transpek Industry share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,249.00 | +0.5% |
| 1 month ago · 1 Oct 2026 | ₹1,310.00 | −4.1% |
| 6 months ago · 30 Apr 2026 | ₹1,192.20 | +5.3% |
| 1 year ago · 31 Oct 2025 | ₹1,427.30 | −12.0% |
| 3 years ago · 3 Nov 2023 | ₹1,802.05 | −30.3% |
| 5 years ago · 4 Nov 2021 | ₹2,440.30 | −48.5% |
| 10 years ago · 4 Nov 2016 | ₹493.40 | +154.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹368.00 | +241.3% |
| Highest weekly close since March 2016 · 4 Nov 2021 | ₹2,440.30 | −48.5% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹345.70 | +263.3% |
| 52-week high (weekly close) · 31 Aug 2026 | ₹1,438.80 | −12.7% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹909.25 | +38.1% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Transpek Industry? 3 Nov 2026: Transpek Industry closed at ₹1,255.80, up 0.5% on the week and down 4.1% on the month. 7 Sep 2026: ex-date for a dividend of ₹20 a share. ### Earlier

- 20 Aug 2026: Transpek Industry held its results call for April to June 2026. Management guided: FY27 revenue growth framed at 15-20%, with at least 15% stated; an added high-volume acid chloride goals about ₹15 crore versus ₹4 crore last year. - Results for April to June 2026: Revenue down 2.1% and profit down 42.7% on a year earlier. ## What dividend does Transpek Industry pay? Transpek Industry paid ₹20 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.59% at the ₹1,255.80 close on 3 November 2026. The last was a dividend of ₹20 a share, ex-date 7 September 2026. ### Transpek Industry dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 7 Sep 2026 | ₹20 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Transpek Industry Ltd paid out 24% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Transpek Industry management say on the latest results call? On the call for April to June 2026, held on 20 August 2026, Transpek Industry's management guided: FY27 revenue growth framed at 15-20%, with at least 15% stated; an added high-volume acid chloride goals about ₹15 crore versus ₹4 crore last year. > “In those cases, we will invest ahead of having a fully confirmed business. However, for quite a few products, the investment is largely driven by customer requirements. We are no longer going to be as conservative as we were.”
> Bimal V. Mehta, on the call for April to June 2026

### What management guided

- Revenue and business size planned to double over the next 5-6 years through current products and new products. - First product: 5 metric tonne pilot, 3-4 month trial and year-end sales; second product: FY27-end commercialization, FY28 revenue and about ₹50 crore annual potential each. - FY27 R&D team and infrastructure to double; Ekalbara multipurpose pilot plant expected ready in 6-7 months, with four reaction streams. - Odisha project: Board review within 25-30 days; if approved, decision by end-November, permissions in 3-4 months and production after 1.5-2 years; about ₹250 crore over 5-6 years, 4-5-year payback. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/885/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 20 August 2026.)

## What to watch in Transpek Industry's next results? When Transpek Industry reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: FY27 revenue growth to reach the stated floor, with added acid-chloride contribution and broader demand recovery visible. - What to check (from the call)
- FY27 revenue growth to reach the stated floor, with added acid-chloride contribution and broader demand recovery visible. - First new product to clear customer performance validation and move from pilot supply into commercial sales by year-end. - Arclin renewal discussions to begin on schedule, with supply continuity, terms and order visibility maintained. - Odisha feasibility and Board process to advance before land acquisition or construction commitments. ## Which stock lists is Transpek Industry on? Transpek Industry is on 2 of our India lists: Momentum stocks and Dividend stocks. - [Momentum stocks Market cap cr: 694.2314306772583](https://www.sectoralpha.in/momentum-stocks-india)
- [Dividend stocks Regular dividend yield (%): 1.61](https://www.sectoralpha.in/dividend-stocks-india)

## Is Transpek Industry profitable? Transpek Industry Ltd earned ₹8.9 Cr of net profit in the Jun 2026 quarter, −42.7% on the same quarter a year earlier. Full-year FY26 profit was ₹46.0 Cr. Over 10 years profit has grown 8.2% a year on average. That is 5.9% of the quarter's revenue. The same quarter a year earlier earned ₹15.6 Cr. For the full year, FY26 profit was ₹46.0 Cr (−6.1% on the year before). Why profit moved: revenue changed −2.1% on a year earlier and the margin moved −2.3 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −18.6% and revenue −5.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Transpek Industry make, and is it growing? Transpek Industry Ltd reported ₹151 Cr of revenue in the Jun 2026 quarter, −2.1% on the same quarter a year earlier. Over 10 years it has grown 8.1% a year on average. The last full year, FY26, came in at ₹621 Cr. The last four reported quarters add to ₹618 Cr. FY26 revenue was ₹621 Cr, −4.5% on the year before. Recent pace: the last four quarters grew −5.2% on average, against 8.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −5.2%, against +4.2% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −29.1%, against +10.4% a year (rolling over). ## How much of every ₹100 of sales does Transpek Industry keep? Transpek Industry Ltd's operating margin was 13.3% in the Jun 2026 quarter, 2.3 percentage points lower than the same quarter a year ago. Across 13 years it has been between 10.0% and 21.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.3 percentage points on the year while gross margin changed +1.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Transpek Industry's profit turning into cash? Over the last 3 years, 232% of Transpek Industry Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹78.0 Cr of operating cash against ₹46.0 Cr of profit. After ₹32.0 Cr of spending on assets, ₹46.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 232% of profit came in as cash: the cash cycle got 19 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Transpek Industry's cash go? Transpek Industry Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 64 days in FY26, down from 83 days in FY21. It spent ₹96.0 Cr on assets over the last 3 years. Customers take 88 days to pay, and stock sits for 63 days on average. At FY26 sales of ₹621 Cr, each day of that cycle ties up about ₹1.7 Cr, so roughly ₹109 Cr is tied up in the business at any time. FY26: customers took 88 days to pay and stock sat for 63 days, about 2.1 months of sales sitting as stock, for a full cycle of 64 days, shorter than FY21's 83. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 63 days. Customers pay about 88 days after that. Suppliers are paid at 87 days. Together that makes the 64-day cycle. Spending on assets: ₹96.0 Cr over the last 3 years, against ₹137 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹5.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Transpek Industry's P/E ratio, and how does it compare with its own history? Transpek Industry Ltd's P/E is 18.0×, in the middle of its own history: higher than 59% of past readings. Its usual P/E (the middle reading) is 15.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −6.3% while the price moved −12.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −12.4% a year; about +3.4% a year came from earnings growth and about −15.8 percentage points from the multiple (the market paying less); over 10 years the price moved +9.8% a year; about +6.3% a year came from earnings growth and about +3.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 4.4% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Transpek Industry business getting better or worse? Transpek Industry Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −5.2% in the latest quarter, against +14.6% at its best in 12 quarters, with ROCE falling at 8.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Transpek Industry earn on its capital? Transpek Industry Ltd earned a ROCE of 8% in FY26. That is up from a low of 7% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 7.4% net margin and 0.62× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 7.4% net margin × 0.62× asset turnover × 1.31× leverage (assets divided by equity) ≈ 6.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.4% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Transpek Industry have too much debt? Transpek Industry Ltd had ₹74.0 Cr of borrowings against ₹768 Cr of equity in FY26, so its debt is 0.10× its equity. Its operating profit is 12 times its interest bill. Over 5 years borrowings went from ₹111 Cr to ₹74.0 Cr. Over the last 3 of those years it spent ₹96.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.4% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Transpek Industry shareholding pattern? Domestic institutions cut their stake in Transpek Industry Ltd by 1.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 0.2% of the company. Foreign institutions moved +1.2 points over the same period, to 1.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −1.7 points over 8 quarters, to 0.2%; Foreign institutions: +1.2 points over 8 quarters, to 1.2%; Promoters: −0.2 points over 8 quarters, to 57.3%. Why the owners changed: domestic institutions drove it (−1.7 points), with the other side taken by foreign institutions (+1.2 points). They reduced their stake. ## How far is Transpek Industry from balance-sheet trouble? For Transpek Industry Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Transpek Industry rank in its industry? 38.6 out of 100, rank 27 of 30 in Speciality Chemicals, with 63% of the evidence available. Transpek Industry Ltd scores 38.6 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 27. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 7.7 + 9.8 + 9.8 + 11.3 = 38.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Transpek Industry compared with? Transpek Industry ranks 27 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 38.6 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · turning · Sector-leading setup · 96% evidence 80.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.8/35 · Revenue 45.9% · Profit 100% · Operating margin change 14 points · 88% evidence Capital efficiency 15.9/25 · ROCE 19.2% · Operating margin 22% · 100% evidence Valuation 19.7/20 · P/E 5.7× · PEG 0.18 · 100% evidence Relative strength 13.9/20 · Lead over its industry 16.3% · Lead over NIFTY 500 31.3% · 1 year 68.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 30.8 + 15.9 + 19.7 + 13.9 = 80.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Most evidence points up · 78% evidence 67.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 8.9% · Operating margin 21% · 100% evidence Valuation 12.7/20 · P/E 45× · PEG 1.02 · 65% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 41.1% · 1 year 103.4% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30 + 12.3 + 12.7 + 12.2 = 67.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 68% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change 8 points · 83% evidence Capital efficiency 21.3/25 · ROCE 36.2% · Operating margin 48% · 95% evidence Valuation 6.6/20 · P/E 25.8× · PEG n/a · 50% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 74.5% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 21.3 + 6.6 + 12.5 = 64.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 12.9% · Profit 100% · Operating margin change 5 points · 88% evidence Capital efficiency 18.8/25 · ROCE 19.9% · Operating margin 16% · 100% evidence Valuation 10.8/20 · P/E 24.3× · PEG 2.21 · 100% evidence Relative strength 10.8/20 · Lead over its industry n/a · Lead over NIFTY 500 4.3% · 1 year -4% · 25% evidence · 0 of 5 weeks ahead Exact sum: 23.6 + 18.8 + 10.8 + 10.8 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Evidence leans up · 81% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 8.6% · Profit 28.6% · Operating margin change 6 points · 88% evidence Capital efficiency 16.4/25 · ROCE 18.7% · Operating margin 16% · 100% evidence Valuation 10.0/20 · P/E 17.1× · PEG 4.96 · 100% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 4.4% · 1 year n/a · 25% evidence · 7 of 12 weeks ahead Exact sum: 23.6 + 16.4 + 10 + 10.9 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) TATVA · losing its lead · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.7/25 · ROCE 7.2% · Operating margin 19% · 100% evidence Valuation 11.3/20 · P/E 60.2× · PEG 1.21 · 65% evidence Relative strength 11.4/20 · Lead over its industry 7.8% · Lead over NIFTY 500 23.3% · 1 year 15.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.7 + 8.7 + 11.3 + 11.4 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · leader · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 30.2% · Profit 28.4% · Operating margin change 1 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.9% · Operating margin 32% · 100% evidence Valuation 9.7/20 · P/E 85.1× · PEG n/a · 50% evidence Relative strength 14.8/20 · Lead over its industry 22.3% · Lead over NIFTY 500 38.6% · 1 year 114.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.4 + 12.8 + 9.7 + 14.8 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.5/25 · ROCE 22.3% · Operating margin 26% · 76% evidence Valuation 10.1/20 · P/E 33.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Lead over its industry -9.7% · Lead over NIFTY 500 4.2% · 1 year 10.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 23.7 + 18.5 + 10.1 + 7.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 96% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.3/35 · Revenue 91.5% · Profit 41% · Operating margin change -2 points · 88% evidence Capital efficiency 13.5/25 · ROCE 18.3% · Operating margin 16% · 100% evidence Valuation 5.7/20 · P/E 46.1× · PEG 1.92 · 100% evidence Relative strength 19.5/20 · Lead over its industry 34.1% · Lead over NIFTY 500 48.9% · 1 year 62.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.3 + 13.5 + 5.7 + 19.5 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans up · 93% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 72.1% · Profit 34.5% · Operating margin change -6.9 points · 100% evidence Capital efficiency 8.7/25 · ROCE 14.8% · Operating margin 4.2% · 100% evidence Valuation 16.1/20 · P/E 16.9× · PEG 0.44 · 65% evidence Relative strength 7.8/20 · Lead over its industry -12.3% · Lead over NIFTY 500 0.9% · 1 year -15.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22.9 + 8.7 + 16.1 + 7.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative
12. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · leader · Evidence leans up · 81% evidence 53.9 out of 100 Growth Capital Valuation Relative
13. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative
14. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative
15. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) KRONOX · breaking out · Evidence leans up · 74% evidence 51.8 out of 100 Growth Capital Valuation Relative
16. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) NEOGEN · leader · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative
17. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 85% evidence 51.1 out of 100 Growth Capital Valuation Relative
18. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans down · 96% evidence 47.9 out of 100 Growth Capital Valuation Relative
19. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) GRAUWEIL · breaking out · Evidence leans down · 96% evidence 46.3 out of 100 Growth Capital Valuation Relative
20. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans down · 85% evidence 45.8 out of 100 Growth Capital Valuation Relative
21. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 53% evidence 44.0 out of 100 Growth Capital Valuation Relative
22. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ANURAS · turning · Evidence leans down · 78% evidence 43.7 out of 100 Growth Capital Valuation Relative
23. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 81% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 42.4 out of 100 Growth Capital Valuation Relative
25. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 41.5 out of 100 Growth Capital Valuation Relative
26. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
27. Transpek Industry Ltd this page TRANSPEK · losing its lead · Evidence leans down · 63% evidence 38.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.7/35 · Revenue -5.2% · Profit -29.1% · Operating margin change -2.3 points · 83% evidence Capital efficiency 9.8/25 · ROCE 8.4% · Operating margin 13.3% · 76% evidence Valuation 9.8/20 · P/E 17.5× · PEG n/a · 50% evidence Relative strength 11.3/20 · Lead over its industry n/a · Lead over NIFTY 500 10.2% · 1 year -13.4% · 25% evidence · 9 of 12 weeks ahead Exact sum: 7.7 + 9.8 + 9.8 + 11.3 = 38.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 28. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 100% evidence 38.4 out of 100 Growth Capital Valuation Relative
29. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · breaking out · Evidence leans down · 85% evidence 38.1 out of 100 Growth Capital Valuation Relative
30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 68% evidence 27.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Transpek Industry in size? Transpek Industry is the 25th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sunshield Chemicals, Amines & Plasticizers and Kronox Lab Sciences. Just below it: Chemcon Speciality Chemicals, Amal and DMCC Speciality Chemicals. ### Speciality Chemicals companies close in size

1. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) ₹882 crore
2. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) ₹782 crore
3. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) ₹691 crore
4. Transpek Industry Ltd ₹682 crore
5. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) ₹666 crore
6. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) ₹658 crore
7. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) ₹634 crore

[All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies)

### Companies close in size in other industries

1. [New Delhi Television Ltd](https://www.sectoralpha.in/stocks/new-delhi-television-ltd) ₹682 crore · Entertainment & Media
2. [Sadhana Nitro Chem Ltd](https://www.sectoralpha.in/stocks/sadhana-nitro-chem-ltd) ₹682 crore · Dyes & Pigments
3. Transpek Industry Ltd ₹682 crore
4. [L. T. Elevator Ltd](https://www.sectoralpha.in/stocks/l-t-elevator-ltd) ₹680 crore
5. [JITF Infra Logistics Ltd](https://www.sectoralpha.in/stocks/jitf-infra-logistics-ltd) ₹678 crore · Logistics

## What else do people ask about Transpek Industry? ### What is Transpek Industry's share price today? Transpek Industry Ltd's share price is ₹1,255.80, −12.0% over the past year. The whole company is worth ₹701 Cr on the market. In the last 52 weeks it traded between ₹909 to ₹1,439; today it is 65% of the way up from the low, 2.3% above its 200-day average (as of 3 November 2026). ### What were Transpek Industry's latest quarterly results? Transpek Industry Ltd reported revenue of ₹151 Cr and net profit of ₹8.9 Cr for the Jun 2026 quarter. Revenue fell 2.1% and profit fell 42.7% compared with a year earlier. Earnings per share were ₹15.99. The operating margin was 13.3%, 2.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Transpek Industry's market cap? Transpek Industry Ltd's market capitalisation is ₹701 Cr at a share price of ₹1,255.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Transpek Industry performing? Transpek Industry Ltd's share price has been rising for 8 weeks. In its latest quarter, revenue fell 2.1% and profit fell 42.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 17 weeks running (as of 3 November 2026). ### Will Transpek Industry's share price go up? This page does not forecast Transpek Industry Ltd's share price. What it shows instead: the share price is ₹1,255.80, and it has been rising for 8 weeks. Its P/E of 18.0× is higher than 59% of its own last 11 years (as of 3 November 2026). ### Who owns Transpek Industry? Promoters own 57.3% of Transpek Industry Ltd, foreign institutions 1.2%, domestic institutions 0.2% and the public 41.3% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 1.7 percentage points over 8 quarters (as of 3 November 2026). ### Where is Transpek Industry in its business cycle? Transpek Industry Ltd's FY26 operating margin was 15.0%, against a 13-year range of 10.0% to 21.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 13.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Transpek Industry story? Biggest thing to watch: the price has already been rising for 8 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Transpek Industry a stock worth studying right now? What the numbers show: Transpek Industry Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Transpek Industry share price forecast for 2026? What management itself guided: FY27 revenue growth framed at 15-20%, with at least 15% stated; an added high-volume acid chloride goals about ₹15 crore versus ₹4 crore last year. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india

This is research, not advice. We’re not SEBI-registered.